Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Pharma’s Neuroblastoma Therapy Approved for China Use

publication date: Dec 9, 2022

SciClone Pharma’s therapy for high-risk neuroblastoma was approved for use in China under conditional rules. Danyelza is a humanized mAb that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. The drug was developed by New York’s Y-mAbs Therapeutics for pediatric patients one year of age and older along with adult patients who have relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Two years ago, SciClone announced a $120 million agreement to acquire China rights for two neuroblastoma therapies from Y-mAbs. More details....

Stock Symbol: (HK: 6600)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital